Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

OBJECTIVES: Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatmen...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMJ Open
Main Authors: Dane, Faysal, Ozgurdal, Kirhan, Yalçın, Şuayib, Benekli, Mustafa, Aykan, Nuri Faruk, Yücel, İdris, Özkan, Metin, Evrensel, Turkkan, Sevinç, Alper, Coskun, Hasan Şenol, Sanli, Ulus Ali, Kara, Ismail Oguz, Yumuk, Perran Fulden
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2020
Fag:
Oncology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170555/
https://ncbi.nlm.nih.gov/pubmed/32220908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-027665
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker